Mesoblast (MESO) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.85B and a free-cash-flow yield of -2.9%. Over the most recent reported fiscal year, revenue grew 191.4%. Nama's AI scorecard rates it Sell, 3.3 out of 10. On 12-month momentum it ranks in the lagging band of its market.
AI scorecard
Sell · 3.3/10
Negative, at the mild end of Sell. As of Nov 7, 2026.
Momentum
Lagging · -6.6% over 12 months ex. last
Second-worst fifth of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-35.1%
How far the last close sits under the highest price of the past five years.
Market cap
$1.85B
Trailing P/E
—
Price / book
32.4
Price / sales
15.3
FCF yield
-2.9%
Dividend yield
—
Gross margin
80.0%
Operating margin
-33.3%
Net margin
-47.8%
Revenue growth (YoY)
+191.4%
Revenue growth (3-yr annual)
+19.0%
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
0.9
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
MESO earnings
Beat the EPS estimate in 3 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q4 2023
Aug 30, 2023
-$0.29
-$0.30
+3.3%
—
Q3 2023
May 25, 2023
-$0.25
-$0.32
+21.9%
—
Q2 2023
Feb 27, 2023
-$0.33
-$0.28
-17.9%
—
Q1 2023
Nov 22, 2022
-$0.24
-$0.33
+27.3%
—
MESO analyst price target
Median target $37.00 from 2 analysts, ranging $35.00 – $39.00.
Nama's AI scorecard currently rates Mesoblast Sell (3.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is the MESO price target?
The median analyst price target from 2 analysts is $37.00, with a range of $35.00 – $39.00.
Is MESO Shariah compliant?
Nama's AAOIFI-style screen reads Mesoblast as Can't Tell. A figure the screen needs is missing, so it can't tell.